RecruitingPHASE1, PHASE2NCT05791864

A First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With TTX-381 for the Ocular Manifestations Associated With Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease

Studying CLN2 disease

Last synced from ClinicalTrials.gov May 14, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Tern Therapeutics, LLC
Intervention: TTX-381(genetic)
Enrollment: 16 enrolled
Eligibility: All sexes
Timeline: 2023 – 2031

Study locations (2)

University Medical Center Hamburg-Eppendorf (UKE)- Childrens Hospital, Hamburg, Germany
Greater Ormond Street Hospital, London, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05791864 on ClinicalTrials.gov

Other trials for CLN2 disease

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05152914
Intravitreal ERT to Prevent Retinal Disease Progression in Children With CLN2
David L Rogers, MD

See all trials for CLN2 disease →

← Back to all trials